Tumor necrosis factor-alpha gene polymorphism and death due to acute cellular rejection in a subgroup of heart transplant recipients.
Irreversible acute rejection of the transplanted heart usually has a fatal outcome. Predicting which recipients are most likely to reject might allow closer monitoring and modification of treatment protocols to prevent graft loss. Recipients genetically predisposed to produce more TNF-alpha are those who suffer the most acute rejection episodes. Here we show that TNF-alpha genotype is strongly associated with death due to acute cell-mediated heart transplant rejection (Chi-square = 28.57, p < 0.0001). This subgroup of recipients should be given optimally tissue matched transplants and should be treated with the most effective immunosuppressive regimens.
Azzawi
M
M
School of Biological Sciences, University of Manchester, UK.
Hasleton
P S
PS
Turner
D M
DM
Yonan
N
N
Deiraniya
A K
AK
Sinnott
P J
PJ
Hutchinson
I V
IV
D000208:Acute Disease; D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000483:Alleles; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D006580:Genetic Carrier Screening; D005838:Genotype; D006084:Graft Rejection / Q000235:genetics* / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D016027:Heart Transplantation / Q000276:immunology* / Q000401:mortality* / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D011110:Polymorphism, Genetic / Q000276:immunology*; D011239:Prednisolone / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis / Q000235:genetics*
D000276:Adjuvants, Immunologic; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D016572:Cyclosporine; D011239:Prednisolone; D001379:Azathioprine